Literature DB >> 24619598

Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.

Jing Zhu1, Lei Lu, Xiang Cheng, Rongkai Xie, Zhengqiong Chen, Youfei Li, Guilan Lin, Jianmei Liu, Ying Yang.   

Abstract

Several studies have assessed the association of CD95L polymorphism with cervical cancer risk, but the data lack the power to provide compelling evidence. In this study, we aimed to clarify the association through a meta-analysis. A comprehensive search was conducted in PubMed, Embase, and Web of Science. The fixed-effects model was used to calculate odds ratio (OR) with 95 % confidence intervals (CIs). A total of five papers with six case-control studies were derived and finally included in this meta-analysis. The overall estimate did not reveal any significant association between CD95L -844C/T polymorphism and cervical cancer risk. Subgroup analysis in Asian population indicated nonsignificant nevertheless potentially increased risk in CC genotype carriers in comparison with the carriers of CT+TT genotypes (ORCC vs. CT+TT=1.16, 95 % CI=0.99-1.36, P for heterogeneity=0.231). Based on current epidemiological studies, this meta-analysis suggests that CD95L polymorphism may not be a risk factor contributing to cervical cancer development.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619598     DOI: 10.1007/s13277-014-1652-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.

Authors:  Hung-Cheng Lai; Wei-Yu Lin; Ya-Wen Lin; Cheng-Chang Chang; Mu-Hsien Yu; Chia-Chi Chen; Tang-Yuan Chu
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

3.  Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.

Authors:  C Gratas; Y Tohma; C Barnas; P Taniere; P Hainaut; H Ohgaki
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

Review 6.  Apoptosis and lung cancer: a review.

Authors:  Narayan Shivapurkar; Jyotsna Reddy; Preet M Chaudhary; Adi F Gazdar
Journal:  J Cell Biochem       Date:  2003-04-01       Impact factor: 4.429

7.  Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.

Authors:  Isabelle Viard-Leveugle; Sylvie Veyrenc; Lars E French; Christian Brambilla; Elisabeth Brambilla
Journal:  J Pathol       Date:  2003-10       Impact factor: 7.996

8.  A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients.

Authors:  Jianming Wu; Christine Metz; Xiulong Xu; Riichiro Abe; Andrew W Gibson; Jeffrey C Edberg; Jennifer Cooke; Fenglong Xie; Glinda S Cooper; Robert P Kimberly
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

10.  Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans.

Authors:  Koushik Chatterjee; Malin Engelmark; Ulf Gyllensten; Collet Dandara; Lize van der Merwe; Ushma Galal; Margaret Hoffman; Anna-Lise Williamson
Journal:  BMC Res Notes       Date:  2009-11-26
View more
  3 in total

1.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

Review 2.  Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.

Authors:  Shing Cheng Tan; Ravindran Ankathil
Journal:  Tumour Biol       Date:  2015-08-05

3.  Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects.

Authors:  Xiongjie Yu; Yanli Li; Yuandong Yu; Jinhua Lei; Guoxing Wan; Fengjun Cao
Journal:  Onco Targets Ther       Date:  2016-04-06       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.